Tags

Type your tag names separated by a space and hit enter

Effect of acyclovir on bronchoconstriction and urinary leukotriene E4 excretion in aspirin-induced asthma.
J Allergy Clin Immunol. 1998 Dec; 102(6 Pt 1):909-14.JA

Abstract

BACKGROUND

Acyclovir (9-[2-hydroxyethoxymethyl] guanine), an inhibitor of the DNA polymerase of the herpes virus, has been reported to exhibit pharmacologic activity other than antiviral activity, including antiasthmatic effects.

OBJECTIVE

This study was designed to investigate the protective effect of acyclovir on airway responsiveness to the sulpyrine provocation test and to investigate whether this protective activity is associated with a reduction in aspirin-induced excretion of urinary leukotriene E4 (u-LTE4), a marker of cysteinyl leukotriene (LT) overproduction that participates in the pathogenesis of aspirin-induced asthma.

METHODS

We assessed the effects of pretreatment with acyclovir on bronchoconstriction precipitated by inhalation of sulpyrine in 16 adult patients with mild or moderate aspirin-induced asthma; those who were in stable clinical condition and were hyperresponsive to the sulpyrine provocation test were allocated to this study. A double-blind, randomized, cross-over design was used. u-LTE4 was measured by a combined reverse-phase HPLC enzyme immunoassay.

RESULTS

Acyclovir protects against aspirin-induced attacks of asthma through mechanisms unrelated to its bronchodilator property but related to the improvement of bronchial hypersensitivity to sulpyrine; protection was nearly complete in all patients (P <.0001). By contrast, after acyclovir, the maximum level of u-LTE4 in patients was significantly lower than that in control subjects (P <. 01).

CONCLUSION

Our results suggest that acyclovir is not only an antiviral drug but also an inhibitor of analgesic-induced bronchoconstriction, probably acting by inhibiting the release of cysteinyl LTs.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Yoshida S
Institute for Medical Sciences, Fujita Health University School of Medicine, Toyoake, Japan.
Sakamoto H
No affiliation info available
Yamawaki Y
No affiliation info available
Shoji T
No affiliation info available
Akahori K
No affiliation info available
Onuma K
No affiliation info available
Nakagawa H
No affiliation info available
Hasegawa H
No affiliation info available
Amayasu H
No affiliation info available

MeSH

AcyclovirAdministration, OralAdultAnti-Asthmatic AgentsAspirinAsthmaBronchoconstrictionCross-Over StudiesDouble-Blind MethodFemaleForced Expiratory VolumeHumansLeukotriene E4MaleMiddle AgedVital Capacity

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9847430

Citation

Yoshida, S, et al. "Effect of Acyclovir On Bronchoconstriction and Urinary Leukotriene E4 Excretion in Aspirin-induced Asthma." The Journal of Allergy and Clinical Immunology, vol. 102, no. 6 Pt 1, 1998, pp. 909-14.
Yoshida S, Sakamoto H, Yamawaki Y, et al. Effect of acyclovir on bronchoconstriction and urinary leukotriene E4 excretion in aspirin-induced asthma. J Allergy Clin Immunol. 1998;102(6 Pt 1):909-14.
Yoshida, S., Sakamoto, H., Yamawaki, Y., Shoji, T., Akahori, K., Onuma, K., Nakagawa, H., Hasegawa, H., & Amayasu, H. (1998). Effect of acyclovir on bronchoconstriction and urinary leukotriene E4 excretion in aspirin-induced asthma. The Journal of Allergy and Clinical Immunology, 102(6 Pt 1), 909-14.
Yoshida S, et al. Effect of Acyclovir On Bronchoconstriction and Urinary Leukotriene E4 Excretion in Aspirin-induced Asthma. J Allergy Clin Immunol. 1998;102(6 Pt 1):909-14. PubMed PMID: 9847430.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of acyclovir on bronchoconstriction and urinary leukotriene E4 excretion in aspirin-induced asthma. AU - Yoshida,S, AU - Sakamoto,H, AU - Yamawaki,Y, AU - Shoji,T, AU - Akahori,K, AU - Onuma,K, AU - Nakagawa,H, AU - Hasegawa,H, AU - Amayasu,H, PY - 1998/12/16/pubmed PY - 1998/12/16/medline PY - 1998/12/16/entrez SP - 909 EP - 14 JF - The Journal of allergy and clinical immunology JO - J Allergy Clin Immunol VL - 102 IS - 6 Pt 1 N2 - BACKGROUND: Acyclovir (9-[2-hydroxyethoxymethyl] guanine), an inhibitor of the DNA polymerase of the herpes virus, has been reported to exhibit pharmacologic activity other than antiviral activity, including antiasthmatic effects. OBJECTIVE: This study was designed to investigate the protective effect of acyclovir on airway responsiveness to the sulpyrine provocation test and to investigate whether this protective activity is associated with a reduction in aspirin-induced excretion of urinary leukotriene E4 (u-LTE4), a marker of cysteinyl leukotriene (LT) overproduction that participates in the pathogenesis of aspirin-induced asthma. METHODS: We assessed the effects of pretreatment with acyclovir on bronchoconstriction precipitated by inhalation of sulpyrine in 16 adult patients with mild or moderate aspirin-induced asthma; those who were in stable clinical condition and were hyperresponsive to the sulpyrine provocation test were allocated to this study. A double-blind, randomized, cross-over design was used. u-LTE4 was measured by a combined reverse-phase HPLC enzyme immunoassay. RESULTS: Acyclovir protects against aspirin-induced attacks of asthma through mechanisms unrelated to its bronchodilator property but related to the improvement of bronchial hypersensitivity to sulpyrine; protection was nearly complete in all patients (P <.0001). By contrast, after acyclovir, the maximum level of u-LTE4 in patients was significantly lower than that in control subjects (P <. 01). CONCLUSION: Our results suggest that acyclovir is not only an antiviral drug but also an inhibitor of analgesic-induced bronchoconstriction, probably acting by inhibiting the release of cysteinyl LTs. SN - 0091-6749 UR - https://www.unboundmedicine.com/medline/citation/9847430/Effect_of_acyclovir_on_bronchoconstriction_and_urinary_leukotriene_E4_excretion_in_aspirin_induced_asthma_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S009167499800445X DB - PRIME DP - Unbound Medicine ER -